Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
3 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptose Bioscns
(TSX:
APS
)
0.5300
-0.0200 (-3.64%)
Streaming Delayed Price
Updated: 2:11 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptose Bioscns
< Previous
1
2
Next >
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Second Quarter 2024
August 08, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
July 19, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 03, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 31, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the First Quarter 2024
May 14, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
May 06, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2023
March 26, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
March 18, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
January 31, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
January 26, 2024
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
November 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
October 16, 2023
Company to Hold Clinical Update Webcast; Details Forthcoming
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
September 18, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
September 06, 2023
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Second Quarter 2023
August 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
June 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Highlights from Clinical Update
June 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Provides Update on Reverse Stock Split
June 05, 2023
Common Shares to begin trading on adjusted basis June 6
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.